{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:04:59Z","timestamp":1792105499691,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T00:00:00Z","timestamp":1347062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00059-012-3671-4","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T08:21:35Z","timestamp":1346919695000},"page":"202-209","source":"Crossref","is-referenced-by-count":16,"title":["Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI","Voraussage myokardialer Reperfusion und schwerer kardialer Ereignisse durch erh\u00f6hten YKL-40-Serumspiegel bei station\u00e4ren Patienten mit STEMI"],"prefix":"10.1007","volume":"38","author":[{"given":"M.","family":"\u00c7etin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Kocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"\u00c7anga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"K\u0131rba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6","family":"Akg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"U\u011furlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Durako\u011flugil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,8]]},"reference":[{"key":"3671_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","volume":"331","author":"Liuzzo","year":"1994","unstructured":"Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417\u2013424","journal-title":"N Engl J Med"},{"key":"3671_CR2","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1161\/01.CIR.96.12.4204","volume":"96","author":"Toss","year":"1997","unstructured":"Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204\u20134210","journal-title":"Circulation"},{"key":"3671_CR3","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","volume":"268","author":"Hakala","year":"1993","unstructured":"Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product protein family. J Biol Chem 268:25803\u201325810","journal-title":"J Biol Chem"},{"key":"3671_CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/geno.1997.4778","volume":"43","author":"Rehli","year":"1997","unstructured":"Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43:221\u2013225","journal-title":"Genomics"},{"key":"3671_CR5","first-page":"172","volume":"53","author":"Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172\u2013209","journal-title":"Dan Med Bull"},{"key":"3671_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/geno.1997.4778","volume":"43","author":"Rehli","year":"1997","unstructured":"Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2):221\u2013225","journal-title":"Genomics"},{"key":"3671_CR7","doi-asserted-by":"crossref","unstructured":"Johansen JS, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 38:618\u2013626","DOI":"10.1093\/rheumatology\/38.7.618"},{"key":"3671_CR8","first-page":"351","volume":"110","author":"Volck","year":"1998","unstructured":"Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351\u2013360","journal-title":"Proc Assoc Am Physicians"},{"key":"3671_CR9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/1529-0131(200104)44:4<826::AID-ANR139>3.0.CO;2-U","volume":"44","author":"Johansen","year":"2001","unstructured":"Johansen JS, Olee T, Price PA et al (2001) Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 44:826\u2013837","journal-title":"Arthritis Rheum"},{"key":"3671_CR10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/excr.1999.4511","volume":"250","author":"Malinda","year":"1999","unstructured":"Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38\u00a0k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168\u2013173","journal-title":"Exp Cell Res"},{"key":"3671_CR11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","volume":"15","author":"Johansen","year":"2006","unstructured":"Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL- 40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194\u2013202","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3671_CR12","doi-asserted-by":"crossref","first-page":"44058","DOI":"10.1074\/jbc.M306792200","volume":"278","author":"Rehli","year":"2003","unstructured":"Rehli M, Niller HH, Ammon C (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 278:44058\u201344067","journal-title":"J Biol Chem"},{"key":"3671_CR13","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9","volume":"43","author":"Baeten","year":"2000","unstructured":"Baeten D, Boots AM, Steenbakkers PG (2000) Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43:1233\u20131243","journal-title":"Arthritis Rheum"},{"key":"3671_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-1119(94)00756-I","volume":"153","author":"Kirkpatrick","year":"1995","unstructured":"Kirkpatrick RB, Matico RE, McNulty DE et al (1995) An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 153:147\u2013154","journal-title":"Gene"},{"key":"3671_CR15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jlb.60.4.540","volume":"60","author":"Krause","year":"1996","unstructured":"Krause SW, Rehli M, Kreutz M et al (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 60:540\u2013545","journal-title":"J Leukoc Biol"},{"key":"3671_CR16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cardfail.2010.05.029","volume":"16","author":"Olga","year":"2010","unstructured":"Olga B, Yasuchika T, Tatsuro K et al (2010) Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 16(11):873\u2013879 doi:10.1016\/j.cardfail.2010.05.029","journal-title":"J Card Fail"},{"key":"3671_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MCA.0b013e328241d991","volume":"18","author":"Kucura","year":"2007","unstructured":"Kucura M, Isman FK, Karadag B et al (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18:391\u2013396","journal-title":"Coron Artery Dis"},{"key":"3671_CR18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/eurheartj\/ehp049","volume":"30","author":"Kastrup","year":"2009","unstructured":"Kastrup J, Johansen JS, Winkel P et al (2009) CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30(9):1066\u20131072","journal-title":"Eur Heart J"},{"key":"3671_CR19","first-page":"10","volume":"doi","author":"Yasuda","year":"2010","unstructured":"Yasuda T, Kaneto H, Katakami N et al (2010) YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract doi:10.1016\/j.diabres.2010.11.015","journal-title":"Diabetes Res Clin Pract"},{"key":"3671_CR20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ana.22220","volume":"68","author":"Kjaergaard","year":"2010","unstructured":"Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68(5):672\u2013680","journal-title":"Ann Neurol"},{"key":"3671_CR21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/europace\/eup103","volume":"11","author":"Henningsen","year":"2000","unstructured":"Henningsen KM, Therkelsen SK, Johansen JS et al (2000) Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 11(8):1032\u20131036","journal-title":"Europace"},{"key":"3671_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9149(67)90023-9","volume":"20","author":"Killip","year":"1967","unstructured":"Killip T III, Kimball JT (1967) Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 20:457\u2013464","journal-title":"Am J Cardiol"},{"key":"3671_CR23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(01)06649-1","volume":"358","author":"Morrow","year":"2001","unstructured":"Morrow DA, Antman EM, Giugliano RP et al (2001) A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358:1571\u20131575","journal-title":"Lancet"},{"key":"3671_CR24","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/01.CIR.102.17.2031","volume":"102","author":"Morrow","year":"2000","unstructured":"Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031\u20132037","journal-title":"Circulation"},{"key":"3671_CR25","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","volume":"116","author":"Thygesen","year":"2007","unstructured":"Thygesen K, Alpert JS, White HD (2007) Joint ESC\/ACCF\/AHA\/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 116:2634\u20132653","journal-title":"Circulation"},{"key":"3671_CR26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","volume":"36","author":"Alpert","year":"2000","unstructured":"Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined\u2014a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959\u2013969","journal-title":"J Am Coll Cardiol"},{"key":"3671_CR27","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/01.CIR.0000147778.05979.E6","volume":"110","author":"Schroder","year":"2004","unstructured":"Schroder R (2004) Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110:e506\u2013510","journal-title":"Circulation"},{"key":"3671_CR28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.107.188209","volume":"117","author":"Antman","year":"2008","unstructured":"Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC\/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 117:296\u2013329","journal-title":"Circulation"},{"key":"3671_CR29","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/01.CIR.87.6.1829","volume":"87","author":"Anderson","year":"1993","unstructured":"Anderson JL, Karagounis LA, Becker LC et al (1993) TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 87:1829\u20131839","journal-title":"Circulation"},{"key":"3671_CR30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","volume":"93","author":"Gibson","year":"1996","unstructured":"Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitativemethod of assessing coronary artery flow. Circulation 93:879\u2013888","journal-title":"Circulation"},{"key":"3671_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.101.2.125","volume":"101","author":"Gibson","year":"2000","unstructured":"Gibson CM, Cannon CP, Murphy SA et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101:125\u2013130","journal-title":"Circulation"},{"key":"3671_CR32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0735-1097(03)00506-0","volume":"42","author":"Gibson","year":"2003","unstructured":"Gibson CM, Karha J, Murphy SA et al (2003) Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 42:7\u201316","journal-title":"J Am Coll Cardiol"},{"key":"3671_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1349-7006.2005.00026.x","volume":"96","author":"Junker","year":"2005","unstructured":"Junker N, Johansen JS, Hansen LT et al (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96:183\u2013190","journal-title":"Cancer Sci"},{"key":"3671_CR34","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"Hansson","year":"2005","unstructured":"Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685\u20131695","journal-title":"N Engl J Med"},{"key":"3671_CR35","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1074\/jbc.270.22.13076","volume":"270","author":"Shackelton","year":"1995","unstructured":"Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin- binding glycoprotein (gp38\u00a0k) in differentiating vascular smooth muscle cells as amember of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076\u201313083","journal-title":"J Biol Chem"},{"key":"3671_CR36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/excr.1999.4511","volume":"250","author":"Malinda","year":"1999","unstructured":"Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38\u00a0k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168\u2013173","journal-title":"Exp Cell Res"},{"key":"3671_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-4827(03)00069-7","volume":"287","author":"Nishikaw","year":"2003","unstructured":"Nishikaw KC, Millis AJ (2003) Gp38\u00a0k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79\u201387","journal-title":"Exp Cell Res"},{"key":"3671_CR38","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/eurheartj\/ehp049","volume":"30","author":"Kastrup","year":"2009","unstructured":"Kastrup J, Johansen JS, Winkel P (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30:1066\u20131072","journal-title":"Eur Heart J"},{"key":"3671_CR39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MCA.0b013e3282f40dd5","volume":"19","author":"Nojgaard","year":"2008","unstructured":"Nojgaard C, Host NB, Christensen IJ (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19:257\u2013263","journal-title":"Coron Artery Dis"},{"key":"3671_CR40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/00365510903518191","volume":"70","author":"Hedegaard","year":"2010","unstructured":"Hedegaard A, Sejersten RR, Johansen JS et al (2010) Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 70:80\u201386","journal-title":"Scand J Clin Lab Invest"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-012-3671-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-012-3671-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-012-3671-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T10:23:17Z","timestamp":1643365397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-012-3671-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["3671"],"URL":"https:\/\/doi.org\/10.1007\/s00059-012-3671-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,8]]}}}